<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">DVR</journal-id>
<journal-id journal-id-type="hwp">spdvr</journal-id>
<journal-title>Diabetes &amp; Vascular Disease Research</journal-title>
<issn pub-type="ppub">1479-1641</issn>
<issn pub-type="epub">1752-8984</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1479164111421804</article-id>
<article-id pub-id-type="publisher-id">10.1177_1479164111421804</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical and biochemical predictors of increased carotid intima-media thickness in overweight and obese adolescents with type 2 diabetes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kotb</surname><given-names>Nesreen A</given-names></name>
<xref ref-type="aff" rid="aff1-1479164111421804">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gaber</surname><given-names>Rania</given-names></name>
<xref ref-type="aff" rid="aff2-1479164111421804">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Salama</surname><given-names>Mai</given-names></name>
<xref ref-type="aff" rid="aff2-1479164111421804">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nagy</surname><given-names>Hala M</given-names></name>
<xref ref-type="aff" rid="aff3-1479164111421804">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Elhendy</surname><given-names>Abdou</given-names></name>
<xref ref-type="aff" rid="aff4-1479164111421804">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-1479164111421804"><label>1</label>Department of Internal Medicine, Tanta University, Tanta, Egypt</aff>
<aff id="aff2-1479164111421804"><label>2</label>Department of Cardiology, Tanta University, Tanta, Egypt</aff>
<aff id="aff3-1479164111421804"><label>3</label>Department of Clinical Pathology, Tanta University, Tanta, Egypt</aff>
<aff id="aff4-1479164111421804"><label>4</label>Department of Cardiology, Marshfield Clinic, Marshfield, WI, USA</aff>
<author-notes>
<corresp id="corresp1-1479164111421804">Abdou Elhendy, Cardiology Department, Marshfield Clinic, 1000 N Oak Ave, Marshfield, WI 54449, USA. Email: <email>Elhendy.abdou@marshfieldclinic.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>9</volume>
<issue>1</issue>
<fpage>35</fpage>
<lpage>41</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><bold>Objective</bold>: To identify the clinical parameters associated with increased carotid intima-media thickness (CIMT) in overweight and obese adolescents with type 2 diabetes.</p>
<p><bold>Methods</bold>: We studied 27 patients (11 males) with type 2 diabetes. Criteria for selection were age (12–19 years), body mass index above the 95th percentile for age and gender, a positive family history of diabetes, normal or high C-peptide, and negative studies for islet cell antibodies. Age- and gender-matched healthy subjects were selected as the control group. Measurements of CIMT, lipid profile, hypersensitive C-reactive protein, hemoglobin A1C (HbA1C), and insulin resistance by homeostasis model of assessment (HOMA) were obtained for all participants.</p>
<p><bold>Results</bold>: CIMT was higher in diabetic patients than in healthy subjects (0.68 ± 0.16 vs. 0.58 ± 0.1, <italic>p</italic> &lt; 0.01). The range of HbA1C in the 15 patients with uncontrolled diabetes was 7.6–10.4 (mean: 8.9 ± 0.9). CIMT, HbA1C, systolic blood pressure, triglycerides, HOMA, and C-reactive protein were significantly higher in patients with uncontrolled than with controlled diabetes. In diabetic patients, CIMT correlated positively with body mass index (<italic>p</italic> &lt; 0.001), duration of diabetes (<italic>p</italic> &lt; 0.001), systolic (<italic>p</italic> &lt; 0.001) and diastolic blood pressure (<italic>p</italic> &lt; 0.01), HbA1C (<italic>p</italic> &lt; 0.001), HOMA (<italic>p</italic> &lt; 0.01), and C-reactive protein (<italic>p</italic> &lt; 0.01).</p>
<p><bold>Conclusions</bold>: CIMT is increased in adolescents with type 2 diabetes. Poor glycemic control, HOMA, increased C-reactive protein, body mass index, duration of diabetes, and elevated blood pressure are associated with early atherosclerosis in these patients.</p>
</abstract>
<kwd-group>
<kwd>Adolescent</kwd>
<kwd>cardiovascular disease</kwd>
<kwd>carotid intima-media thickness</kwd>
<kwd>type 2 diabetes</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1479164111421804" sec-type="intro">
<title>Introduction</title>
<p>Early-onset type 2 diabetes is a serious health concern for children and adolescents, as a significant portion of their lives will be spent controlling this disease. Poor long-term glycemic control can lead to significant morbidity, including macrovascular and microvascular complications.<sup><xref ref-type="bibr" rid="bibr1-1479164111421804">1</xref></sup> Type 2 diabetes in children and adolescents is due to a combination of insulin resistance and relative B-cell failure.<sup><xref ref-type="bibr" rid="bibr2-1479164111421804">2</xref></sup> Risk factors include a family history of type 2 diabetes,<sup><xref ref-type="bibr" rid="bibr3-1479164111421804">3</xref></sup> obesity, and increased abdominal fat.<sup><xref ref-type="bibr" rid="bibr3-1479164111421804">3</xref>-<xref ref-type="bibr" rid="bibr5-1479164111421804">5</xref></sup></p>
<p>Carotid intima-media thickness (CIMT) is a marker of generalized atherosclerosis that correlates with the extent of coronary artery disease in adults and predicts future cardiovascular events.<sup><xref ref-type="bibr" rid="bibr6-1479164111421804">6</xref>-<xref ref-type="bibr" rid="bibr8-1479164111421804">8</xref></sup> Several studies have shown an association between increased CIMT with myocardial infarction and stroke in old and middle-aged subjects. Factors associated with increased CIMT in the adult population include hypertension, dyslipidemia, obesity, and diabetes.<sup><xref ref-type="bibr" rid="bibr9-1479164111421804">9</xref></sup> Studies of the association of CIMT with clinical and biochemical parameters in adolescents with type 2 diabetes are scarce. The aim of this study was to identify the clinical parameters associated with increased CIMT in overweight and obese adolescents with type 2 diabetes.</p>
</sec>
<sec id="section2-1479164111421804" sec-type="methods">
<title>Methods</title>
<p>The study protocol was approved by the Research Committee of Tanta University, Tanta, Egypt. Patients were enrolled from the diabetes outpatient clinic of Tanta University Hospital. Criteria for selection were: age between 12 and 19 years, body mass index above the 95th percentile for age and gender, a positive family history of diabetes, normal or high fasting C-peptide, and negative tests for islet cell antibodies. A control group of age- and gender-matched healthy subjects was also studied. All participants underwent clinical examination. Laboratory investigations included total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, hypersensitive C-reactive protein, and hemoglobin A1C (HbA1C; glycated hemoglobin). Insulin resistance was evaluated using the homeostasis model of assessment (HOMA) calculated as fasting glucose (mmol/L) × fasting insulin (mU/ml)/22.5. According to HbA1C, diabetic patients were divided into patients with controlled diabetes (HbA1C ≤ 6.5) and uncontrolled diabetes (HbA1C &gt; 6.5).</p>
<sec id="section3-1479164111421804">
<title>Biochemical analysis</title>
<p>Blood samples were centrifuged within 20 minutes of collection at 4 °C. Ethylenediaminetetraacetic acid (EDTA) plasma was separated from cells immediately after centrifugation and stored at -80 °C until analyzed. Total cholesterol, triglycerides, and HDL cholesterol were analyzed using standard enzymatic methods. LDL cholesterol was calculated using the Friedewald formula. Hypersensitive C-reactive protein was measured using the immunoturbidimetric technique, as previously described in the literature.<sup><xref ref-type="bibr" rid="bibr10-1479164111421804">10</xref></sup> The percentage of glycated hemoglobin was measured by colorimetric method using kits supplied by Stanbio Laboratory (Boerne, TX, USA). A preparation of whole blood is mixed with a weakly binding cation-exchange resin. The non-glycated hemoglobin binds to the resin, leaving HbA1C to be removed by means of a resin separator in the supernatant.<sup><xref ref-type="bibr" rid="bibr11-1479164111421804">11</xref></sup> Plasma levels of islet cell antibodies, fasting insulin, and fasting C-peptide were measured by sandwich enzyme-linked immunosorbent assay (ELISA) method based on monoclonal antibody (DRG International, Inc., Mountainside, NJ, USA).</p>
</sec>
<sec id="section4-1479164111421804">
<title>Carotid studies</title>
<p>Measurements of CIMT were performed on a common carotid artery. All participants underwent carotid duplex scanning of both carotid arteries. CIMT was evaluated using a high-resolution 7.5 MHz linear transducer in B mode (Vivid 7 ultrasound machine; GE Healthcare, Bethesda, MD, USA). Far-wall measurements were obtained. CIMT of the far wall was defined as the distance between the leading edge of the lumen-intima interface and the leading edge of the media-adventitia interface. CIMT was measured on each side at three sites (thickest point, and at sites 1 cm upstream and downstream, free from plaques) on the longitudinal views. In cases with uniform CIMT, measurements were obtained 1 cm from the bifurcation to the end of the common carotid artery. CIMT was calculated as the average of measurements from three different sites on each side. <xref ref-type="fig" rid="fig1-1479164111421804">Figure 1</xref> shows the measurement of CIMT in a patient with normal CIMT and a patient with increased CIMT.</p>
<fig id="fig1-1479164111421804" position="float">
<label>Figure 1.</label>
<caption>
<p>Measurement of CIMT. Panel (A) shows increased thickness. Panel (B) shows normal thickness.</p>
<p>CIMT, carotid intima-media thickness.</p>
</caption>
<graphic xlink:href="10.1177_1479164111421804-fig1.tif"/>
</fig>
</sec>
<sec id="section5-1479164111421804">
<title>Statistical analysis</title>
<p>Data are presented as mean ± SD. The Student’s <italic>t</italic>-test was used to compare parameters between the two groups. The ANOVA test was used to compare the data between three groups. The Tukey’s test was used to compare data between each two groups. A <italic>p</italic> value of &lt; 0.05 was considered significant. Pearson’s correlation was used to correlate between variables. All statistical analyses were carried out using the SPSS software (version 17; IBM Corporation, Armonk, NY, USA).</p>
</sec>
</sec>
<sec id="section6-1479164111421804" sec-type="results">
<title>Results</title>
<p>Forty-five diabetic patients were selected. Only 27 of them (16 female, 11 male) tested negative for islet cell antibodies, had a high or normal C-peptide, and represented the final population. Seven patients (26%) had a positive family history of coronary heart disease. None of the study patients was receiving medications other than insulin [short-acting insulin plus neutral protamine Hagedorn (NPH) insulin] and metformin. Insulin was indicated due to the inability to control diabetes with metformin alone. The range of HbA1C in the 15 patients with uncontrolled diabetes was 7.6–10.4 while the mean was 8.9 ± 0.9. Twenty-seven age- and gender-matched healthy adolescents were included as a control group. <xref ref-type="table" rid="table1-1479164111421804">Table 1</xref> shows the clinical and laboratory data for diabetic patients. <xref ref-type="table" rid="table2-1479164111421804">Table 2</xref> compares the clinical and biochemical data of the three groups studied. Body mass index, triglycerides, C-reactive protein, HbA1C, and HOMA were significantly increased in controlled and uncontrolled diabetic patients than in healthy subjects. CIMT was significantly increased in uncontrolled diabetic patients than in healthy subjects while there was no statistically significant difference between controlled diabetic patients and healthy subjects regarding CIMT (<xref ref-type="fig" rid="fig2-1479164111421804">Figure 2</xref>). <xref ref-type="table" rid="table3-1479164111421804">Table 3</xref> shows the clinical and biochemical comparisons between diabetic patients and healthy controls.</p>
<table-wrap id="table1-1479164111421804" position="float">
<label>Table 1.</label>
<caption>
<p>Clinical and laboratory data of diabetic patients</p>
</caption>
<graphic alternate-form-of="table1-1479164111421804" xlink:href="10.1177_1479164111421804-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameters</th>
<th align="left">Range</th>
<th align="left">Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>12–19</td>
<td>15.5 ± 2.6</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td>2–8</td>
<td>5.5 ±1.6</td>
</tr>
<tr>
<td>Insulin (units/day)</td>
<td>30–80</td>
<td>67.6 ± 15.8</td>
</tr>
<tr>
<td>Metformin dose (mg/day)</td>
<td>500–1500</td>
<td>925.3 ± 60</td>
</tr>
<tr>
<td>Co-medications</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Body mass index (kg/m<sup>2</sup>)</td>
<td>28.3–35.6</td>
<td>32.9 ± 1.8</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>100–120</td>
<td>109 ± 7</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>65–80</td>
<td>69 ± 5</td>
</tr>
<tr>
<td>Total cholesterol (mg/100ml)</td>
<td>100–170</td>
<td>136 ± 25</td>
</tr>
<tr>
<td>LDL cholesterol (mg/100ml)</td>
<td>50–120</td>
<td>80 ± 21</td>
</tr>
<tr>
<td>HDL cholesterol (mg/100ml)</td>
<td>45–67</td>
<td>56 ± 7</td>
</tr>
<tr>
<td>Triglycerides (mg/100ml)</td>
<td>90–180</td>
<td>140 ± 28</td>
</tr>
<tr>
<td>HbA1C</td>
<td>5.2–10.4</td>
<td>7.5 ± 1.7</td>
</tr>
<tr>
<td>HOMA</td>
<td>2.5–5.6</td>
<td>3.13 ± 0.67</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>3.2–8</td>
<td>5.8 ± 1.5</td>
</tr>
<tr>
<td>C-peptide</td>
<td>0.85–3.6</td>
<td>2.7 ± 0.9</td>
</tr>
<tr>
<td>Carotid intima-media thickness</td>
<td>0.45–0.98</td>
<td>0.68 ± 0.16</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1479164111421804">
<p>HbA1C: hemoglobin A1C (glycated hemoglobin), HDL: high-density lipoprotein, HOMA: homeostasis model assessment, LDL: low-density lipoprotein, N/A: not applicable.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-1479164111421804" position="float">
<label>Table 2.</label>
<caption>
<p>Comparison of clinical and biochemical data of the study groups</p>
</caption>
<graphic alternate-form-of="table2-1479164111421804" xlink:href="10.1177_1479164111421804-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Healthy controls (I)<break/>(<italic>N</italic> = 27)<break/>Male/Female (11/16)</th>
<th align="left">Controlled diabetes (II)<break/>(<italic>N</italic>=12)<break/>Male/Female (5/7)</th>
<th align="left">Uncontrolled diabetes (III)<break/>(<italic>N</italic>=15)<break/>Male/Female (6/9)</th>
<th align="left" colspan="5">ANOVA</th>
</tr>
<tr>
<th/>
<th/>
<th/>
<th/>
<th/>
<th/>
<th align="left" colspan="3">Tukey’s test</th>
</tr>
<tr>
<th/>
<th align="left">Mean ± SD</th>
<th align="left">Mean ± SD</th>
<th align="left">Mean ± SD</th>
<th align="left"><italic>F</italic></th>
<th align="left"><italic>p</italic></th>
<th align="left">I and II</th>
<th align="left">I and III</th>
<th align="left">II and III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body mass index (kg/m<sup>2</sup>)</td>
<td>25.7 ± 1.6</td>
<td>31.5 ± 0.8</td>
<td>32.3 ± 2.3</td>
<td>127</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.4</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>103 ± 5</td>
<td>105 ± 4</td>
<td>112 ± 7</td>
<td>11.9</td>
<td>&lt; 0.001</td>
<td>&gt; 0.05</td>
<td>&lt; 0.001</td>
<td>0.01</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>70 ± 4</td>
<td>68 ± 3</td>
<td>71 ± 6</td>
<td>2.46</td>
<td>0.09</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Total cholesterol (mg/100ml)</td>
<td>134 ± 12</td>
<td>138 ± 25</td>
<td>135 ± 26</td>
<td>0.15</td>
<td>0.9</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>LDL (mg/100ml)</td>
<td>77 ± 7</td>
<td>80 ± 17</td>
<td>81 ± 2</td>
<td>0.37</td>
<td>0.7</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>HDL (mg/100ml)</td>
<td>57 ± 2</td>
<td>56 ± 6</td>
<td>56 ± 7</td>
<td>0.57</td>
<td>0.6</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Triglycerides (mg/100ml)</td>
<td>102 ± 15</td>
<td>116 ± 14</td>
<td>160 ± 20</td>
<td>64</td>
<td>&lt; 0.001</td>
<td>&lt; 0.05</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>HbA1C</td>
<td>4.6 ± 0.5</td>
<td>5.8 ± 0.5</td>
<td>8.9 ± 0.9</td>
<td>221</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>HOMA</td>
<td>0.7 ± 0.1</td>
<td>2.8 ± 0.9</td>
<td>3.4 ± 0.3</td>
<td>199</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>2.6 ± 0.8</td>
<td>4.6 ± 0.8</td>
<td>6.8 ± 1.1</td>
<td>113</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>C-peptide</td>
<td>2.6 ± 0.7</td>
<td>2.9 ± 0.7</td>
<td>2.6 ± 1.0</td>
<td>0.6</td>
<td>0.5</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Carotid intima-media thickness</td>
<td>0.6 ± 0.1</td>
<td>0.63 ± 0.11</td>
<td>0.8 ± 0.2</td>
<td>12</td>
<td>&lt; 0.001</td>
<td>0.07</td>
<td>&lt; 0.01</td>
<td>&lt; 0.05</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1479164111421804">
<p>ANOVA: analysis of variance, HbA1C: hemoglobin A1C (glycated hemoglobin), HDL: high-density lipoprotein, HOMA: homeostasis model assessment, LDL: low-density lipoprotein.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig2-1479164111421804" position="float">
<label>Figure 2.</label>
<caption>
<p>Comparison of CIMT among the three study groups.</p>
<p>CIMT, carotid intima-media thickness.</p>
</caption>
<graphic xlink:href="10.1177_1479164111421804-fig2.tif"/>
</fig>
<table-wrap id="table3-1479164111421804" position="float">
<label>Table 3.</label>
<caption>
<p>Comparison of clinical and biochemical data between diabetic patients and healthy controls</p>
</caption>
<graphic alternate-form-of="table3-1479164111421804" xlink:href="10.1177_1479164111421804-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Healthy controls<break/><italic>N</italic> = 27<break/>Male/Female (11/16)</th>
<th align="left">Diabetic patients<break/><italic>N</italic> = 27<break/>Male/Female (11/16)</th>
<th align="left" colspan="2">Student’s <italic>t</italic>-test</th>
</tr>
<tr>
<th/>
<th align="left">Mean ± SD</th>
<th align="left">Mean ± SD</th>
<th align="left"><italic>t</italic></th>
<th align="left"><italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Body mass index (kg/m<sup>2</sup>)</td>
<td>25.7 ± 1.6</td>
<td>31.9 ± 1.8</td>
<td>13.468</td>
<td>0.000</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>103.0 ± 5.0</td>
<td>108.9 ± 5.9</td>
<td>3.968</td>
<td>0.000</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>70.0 ± 4.0</td>
<td>69.7 ± 4.9</td>
<td>0.273</td>
<td>0.786</td>
</tr>
<tr>
<td>Total cholesterol (mg/100ml)</td>
<td>134 ± 12</td>
<td>136.3 ± 25.6</td>
<td>0.420</td>
<td>0.670</td>
</tr>
<tr>
<td>LDL (mg/100ml)</td>
<td>77.0 ± 7.0</td>
<td>80.6 ± 114</td>
<td>1.383</td>
<td>0.172</td>
</tr>
<tr>
<td>HDL (mg/100ml)</td>
<td>57.0 ± 2.0</td>
<td>56.0 ± 6.6</td>
<td>0.756</td>
<td>0.453</td>
</tr>
<tr>
<td>Triglycerides (mg/100ml)</td>
<td>102 ± 15.</td>
<td>140.4 ± 17.6</td>
<td>8.634</td>
<td>0.000</td>
</tr>
<tr>
<td>HbA1C</td>
<td>4.6 ± 0.5</td>
<td>7.5 ± 0.8</td>
<td>16.829</td>
<td>0.000</td>
</tr>
<tr>
<td>HOMA</td>
<td>0.7 ± 0.1</td>
<td>3.1 ± 0.6</td>
<td>19.576</td>
<td>0.000</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>2.6 ± 0.8</td>
<td>5.8 ± 1.0</td>
<td>13.242</td>
<td>0.000</td>
</tr>
<tr>
<td>C-peptide</td>
<td>2.6 ± 0.7</td>
<td>2.7 ± 0.9</td>
<td>0.614</td>
<td>0.542</td>
</tr>
<tr>
<td>Carotid intima-media thickness</td>
<td>0.6 ± 0.1</td>
<td>0.7 ± 0.2</td>
<td>3.222</td>
<td>0.002</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1479164111421804">
<p>HbA1C: hemoglobin A1C (glycated hemoglobin), HDL: high-density lipoprotein, HOMA: homeostasis model assessment, LDL: low-density lipoprotein.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="table" rid="table4-1479164111421804">Table 4</xref> shows the data of patients with controlled versus uncontrolled diabetes. Triglycerides, C-reactive protein, HbA1C, and HOMA were significantly higher in uncontrolled diabetic patients compared to controlled diabetic patients. HbA1C, systolic blood pressure, triglycerides, HOMA, C-reactive protein, and duration of diabetes were significantly higher in uncontrolled than controlled diabetic patients. There was no significant difference between the diabetic groups with regard to body mass index, diastolic blood pressure, cholesterol, LDL, HDL, and C-peptide (<xref ref-type="table" rid="table4-1479164111421804">Table 4</xref>). CIMT was significantly higher in diabetic patients than in controls (<xref ref-type="table" rid="table3-1479164111421804">Table 3</xref>) and significantly higher in uncontrolled diabetic patients than in controlled diabetic patients (<xref ref-type="table" rid="table4-1479164111421804">Table 4</xref>). CIMT was not significantly different between patients with a family history of cardiovascular disease (0.52 ± 0.45) as compared to patients without (0.73 ± 0.14).</p>
<table-wrap id="table4-1479164111421804" position="float">
<label>Table 4.</label>
<caption>
<p>Comparison of clinical and biochemical data of patients with controlled and uncontrolled diabetes</p>
</caption>
<graphic alternate-form-of="table4-1479164111421804" xlink:href="10.1177_1479164111421804-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Controlled diabetes<break/>(<italic>N</italic> = 12)<break/>Male/Female (5/7)</th>
<th align="left">Uncontrolled diabetes<break/>(<italic>N</italic> = 15)<break/>Male/Female (6/9)</th>
<th align="left" colspan="2">Student’s <italic>t</italic>-test</th>
</tr>
<tr>
<th/>
<th align="left">Mean ± SD</th>
<th align="left">Mean ± SD</th>
<th align="left"><italic>t</italic></th>
<th align="left"><italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes duration (years)</td>
<td>4.6 ± 1.5</td>
<td>6.4 ± 1.6</td>
<td>3.4</td>
<td>0.002</td>
</tr>
<tr>
<td>Body mass index (kg/m<sup>2</sup>)</td>
<td>31.5 ± 0.8</td>
<td>32.3 ± 2.3</td>
<td>13.5</td>
<td>0.400</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>105 ± 4</td>
<td>112.0 ± 7.0</td>
<td>3.96</td>
<td>0.000</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>68 ± 3</td>
<td>71.0 ± 6.0</td>
<td>0.27</td>
<td>0.786</td>
</tr>
<tr>
<td>Total cholesterol (mg/100ml)</td>
<td>138 ± 25</td>
<td>135 ± 26</td>
<td>0.42</td>
<td>0.670</td>
</tr>
<tr>
<td>LDL (mg/100ml)</td>
<td>80.0 ± 17.0</td>
<td>81.0 ± 2.0</td>
<td>1.38</td>
<td>0.172</td>
</tr>
<tr>
<td>HDL (mg/100ml)</td>
<td>56.0 ± 6.0</td>
<td>56.0 ± 7.0</td>
<td>0.76</td>
<td>0.453</td>
</tr>
<tr>
<td>Triglycerides (mg/100ml)</td>
<td>116.0 ± 14.0</td>
<td>160.0 ± 20.0</td>
<td>8.63</td>
<td>0.000</td>
</tr>
<tr>
<td>HbA1C</td>
<td>5.8 ± 0.5</td>
<td>8.9 ± 0.9</td>
<td>16.83</td>
<td>0.000</td>
</tr>
<tr>
<td>HOMA</td>
<td>2.8 ± 0.9</td>
<td>3.4 ± 0.3</td>
<td>19.58</td>
<td>0.000</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>4.6 ± 0.8</td>
<td>6.8 ± 1.1</td>
<td>13.24</td>
<td>0.000</td>
</tr>
<tr>
<td>C-peptide</td>
<td>2.9 ± 0.7</td>
<td>2.6 ± 1.0</td>
<td>0.61</td>
<td>0.542</td>
</tr>
<tr>
<td>Carotid intima-media thickness</td>
<td>0.6 ± 0.1</td>
<td>0.8 ± 0.2</td>
<td>3.2</td>
<td>0.002</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1479164111421804">
<p>HbA1C: hemoglobin A1C (glycated hemoglobin), HDL: high-density lipoprotein, HOMA: homeostasis model assessment, LDL: low-density lipoprotein.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="table" rid="table5-1479164111421804">Table 5</xref> shows the correlation between CIMT and other variables in diabetic patients. CIMT correlated positively with body mass index, systolic and diastolic blood pressure, triglycerides, HbA1C, HOMA, and C-reactive protein. CIMT correlated positively with duration of diabetes in all patients (<italic>p</italic> &lt; 0.001). This correlation was observed in patients with controlled diabetes (<italic>p</italic> &lt; 0.05) as well as in patients with uncontrolled diabetes (<italic>p</italic> &lt; 0.001). There was no correlation between CIMT, age, LDL, HDL, and total cholesterol. <xref ref-type="table" rid="table6-1479164111421804">Table 6</xref> shows the correlation between HbA1C and other variables in diabetic patients. <xref ref-type="fig" rid="fig3-1479164111421804">Figure 3</xref> specifically shows the correlation between CIMT and HbA1C in diabetic patients. HbA1C correlated positively with body mass index, systolic blood pressure, triglycerides, HOMA, C-reactive protein, and CIMT. There was no correlation between HbA1C, diastolic blood pressure, LDL, HDL, and total cholesterol.</p>
<table-wrap id="table5-1479164111421804" position="float">
<label>Table 5.</label>
<caption>
<p>Correlation between CIMT and other variables in diabetic patients</p>
</caption>
<graphic alternate-form-of="table5-1479164111421804" xlink:href="10.1177_1479164111421804-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Variable</th>
<th align="left"><italic>r</italic></th>
<th align="left"><italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes duration</td>
<td>0.9</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Body mass index (kg/m<sup>2</sup>)</td>
<td>0.9</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>0.9</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>0.6</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Total cholesterol (mg/100ml)</td>
<td>0.2</td>
<td>0.5</td>
</tr>
<tr>
<td>LDL (mg/100ml)</td>
<td>–0.3</td>
<td>0.1</td>
</tr>
<tr>
<td>HDL (mg/100ml)</td>
<td>0.1</td>
<td>0.5</td>
</tr>
<tr>
<td>Triglycerides (mg/100ml)</td>
<td>0.7</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>HbA1C</td>
<td>0.6</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>HOMA</td>
<td>0.5</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>0.5</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>C-peptide</td>
<td>–0.1</td>
<td>0.8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1479164111421804">
<p>HbA1C: hemoglobin A1C (glycated hemoglobin), HDL: high-density lipoprotein, HOMA: homeostasis model assessment, LDL: low-density lipoprotein.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table6-1479164111421804" position="float">
<label>Table 6.</label>
<caption>
<p>Correlation between HbA1C and other variables in diabetic patients</p>
</caption>
<graphic alternate-form-of="table6-1479164111421804" xlink:href="10.1177_1479164111421804-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="3">HbA1C</th>
</tr>
<tr>
<th/>
<th align="left"><italic>r</italic></th>
<th align="left"><italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes duration</td>
<td>0.6</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Body mass index (kg/m<sup>2</sup>)</td>
<td>0.6</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>0.5</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>0.2</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Total cholesterol (mg/100ml)</td>
<td>0.1</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>LDL (mg/100ml)</td>
<td>–0.15</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>HDL (mg/100ml)</td>
<td>0.1</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Triglycerides (mg/100ml)</td>
<td>0.7</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>HOMA</td>
<td>0.6</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>0.4</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>C-peptide</td>
<td>–0.14</td>
<td>&gt; 0.05</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-1479164111421804">
<p>HbA1C: hemoglobin A1C (glycated hemoglobin), HDL: high-density lipoprotein, HOMA: homeostasis model assessment, LDL: low-density lipoprotein.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig3-1479164111421804" position="float">
<label>Figure 3.</label>
<caption>
<p>Correlation between CIMT and HbA1C in diabetic patients.</p>
<p>CIMT: carotid intima-media thickness, HbA1C: hemoglobin A1C (glycated hemoglobin).</p>
</caption>
<graphic xlink:href="10.1177_1479164111421804-fig3.tif"/>
</fig>
</sec>
<sec id="section7-1479164111421804" sec-type="discussion">
<title>Discussion</title>
<p>Obesity has led to a dramatic increase in the incidence of type 2 diabetes among children and adolescents over the past two decades. Obesity is strongly associated with insulin resistance, which, when coupled with relative insulin deficiency, leads to the development of overt type 2 diabetes. Children and adolescents with type 2 diabetes may experience vascular complications at younger ages than individuals who develop diabetes in adulthood, including atherosclerotic cardiovascular disease, stroke, myocardial infarction, sudden death, renal insufficiency, neuropathy, and retinopathy leading to blindness.<sup><xref ref-type="bibr" rid="bibr12-1479164111421804">12</xref></sup></p>
<p>Measurement of CIMT using high-resolution B-mode ultrasound is a well-validated, non-invasive method of assessing early cardiovascular disease.<sup><xref ref-type="bibr" rid="bibr13-1479164111421804">13</xref>,<xref ref-type="bibr" rid="bibr14-1479164111421804">14</xref></sup> In type 2 diabetes mellitus, CIMT is significantly higher than in corresponding healthy, age- and gender-matched non-diabetic subjects.<sup><xref ref-type="bibr" rid="bibr15-1479164111421804">15</xref>,<xref ref-type="bibr" rid="bibr16-1479164111421804">16</xref></sup> Although the incidence of cardiovascular disease is increasing among patients with diabetes,<sup><xref ref-type="bibr" rid="bibr17-1479164111421804">17</xref>,<xref ref-type="bibr" rid="bibr18-1479164111421804">18</xref></sup> the role of glycemia in this process remains uncertain.<sup><xref ref-type="bibr" rid="bibr19-1479164111421804">19</xref></sup> Most of the data on the evolution of atherosclerosis in young diabetic patients is driven by autopsy studies. Changes in CIMT are suspected to be reversible at a young age as thickening of the carotid artery wall in younger people consists of more fatty buildup and fewer calcifications.<sup><xref ref-type="bibr" rid="bibr20-1479164111421804">20</xref></sup> Further studies are needed to confirm this.</p>
<p>In the present study CIMT was significantly greater in adolescent with type 2 diabetes than in healthy subjects and correlated positively with the duration of diabetes, body mass index, systolic and diastolic blood pressure, HbA1C, HOMA, and C-reactive protein. Studies of the clinical and biochemical predictors of CIMT in young patients with type 2 diabetes are scarce. Shah <italic>et al</italic>.<sup><xref ref-type="bibr" rid="bibr20-1479164111421804">20</xref></sup> studied 129 patients, aged 10–23, with type 2 diabetes. CIMT was related to the duration of diabetes and to levels of HbA1C. Urbina <italic>et al</italic>.<sup><xref ref-type="bibr" rid="bibr21-1479164111421804">21</xref></sup> compared carotid arteries in young people who were either lean, obese, or had type 2 diabetes. Cardiovascular risk factors worsened from the lean to the obese to the diabetes groups. Diabetic patients had greater CIMT than that measured in lean and obese subjects for the common carotid artery and bulb. Determinants of CIMT were age, gender, and systolic blood pressure.</p>
<p>In our study, there was no significant difference between patients with uncontrolled diabetes, patients with controlled diabetes, and healthy controls in terms of total cholesterol, HDL or LDL, whereas triglycerides were significantly increased in the uncontrolled diabetes group than in the other groups. Although lipoproteins are important biomarkers for vascular risk, they do not completely account for the excess vascular complications in diabetes. Therefore, more recently, plasma biomarkers of inflammation and endothelial dysfunction have been investigated as possible risk factors for diabetic complications. Interleukin 6 (IL-6) and C-reactive protein are known to be increased in obesity and type 2 diabetes.<sup><xref ref-type="bibr" rid="bibr22-1479164111421804">22</xref></sup> Our results showed a significant elevation of hypersensitive C-reactive protein in uncontrolled than in controlled diabetic patients and this correlated positively with CIMT.</p>
<p>Several epidemiological studies have shown that fasting hyperinsulinemia predicts cardiovascular events.<sup><xref ref-type="bibr" rid="bibr23-1479164111421804">23</xref></sup>This was initially interpreted as evidence that insulin is atherogenic. However, because hyperinsulinemia is a reflection of an insulin-resistant state, it is now increasingly accepted that insulin resistance rather than hyperinsulinemia is pro-atherogenic. Recent data suggest that insulin has a potent anti-inflammatory effect that may inhibit atherogenesis in the long term.<sup><xref ref-type="bibr" rid="bibr24-1479164111421804">24</xref></sup> This may also explain why insulin-resistant states may be pro-inflammatory and pro-atherogenic. In our study, HOMA was significantly higher in patients with uncontrolled than with controlled diabetes and it also correlated positively with CIMT.</p>
<p>Finally, in our study, HbA1C correlated positively with CIMT, body mass index, systolic blood pressure, triglycerides, HOMA, and C-reactive protein. Our results demonstrate the significant influence of quality of blood sugar control on CIMT, metabolic parameters, and the importance of effective blood sugar control.</p>
</sec>
<sec id="section8-1479164111421804">
<title>Limitations of the study</title>
<p>One limitation of the study was the small number of patients. We used the HOMA test as a simple, indirect method for assessing insulin resistance, which is less accurate than the gold standard of the hyperinsulinemic euglycemic clamp. Finally, CIMT was measured manually. The use of a semi-automated ultrasound border detection program could further improve the accuracy and efficiency of measurements of CIMT.</p>
</sec>
<sec id="section9-1479164111421804" sec-type="conclusions">
<title>Conclusions</title>
<p>CIMT is a useful tool for the early detection of atherosclerosis in adolescents with type 2 diabetes. Poor glycemic control, HOMA, increased C-reactive protein, body mass index, duration of diabetes, and elevated blood pressure are associated with early atherosclerosis in these patients.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1479164111421804">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinhas-Hamiel</surname><given-names>O</given-names></name>
<name><surname>Zeitler</surname><given-names>P</given-names></name>
</person-group>. <article-title>Clinical presentation and treatment of type 2 diabetes in children</article-title>. <source>Pediatr Diabetes</source> <year>2007</year>; (<issue>Suppl 9</issue>): <fpage>16</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr2-1479164111421804">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sinha</surname><given-names>R</given-names></name>
<name><surname>Fisch</surname><given-names>G</given-names></name>
<name><surname>Teague</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence of impaired glucose tolerance among children and adolescent with marked obesity</article-title>. <source>N Eng J Med</source> <year>2002</year>; <volume>346</volume>: <fpage>802</fpage>–<lpage>810</lpage>.</citation>
</ref>
<ref id="bibr3-1479164111421804">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Congdon</surname><given-names>P</given-names></name>
</person-group>. <article-title>Estimating diabetes prevalence by small area in England</article-title>. <source>J Public Health (Oxf.)</source> <year>2006</year>; <volume>28</volume>: <fpage>71</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr4-1479164111421804">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berenson</surname><given-names>GS</given-names></name>
<name><surname>Srinivasan</surname><given-names>SR</given-names></name>
<name><surname>Wattigney</surname><given-names>WA</given-names></name>
<name><surname>Harsha</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Obesity and cardiovascular risk in children</article-title>. <source>Ann N Y Acad Sci</source> <year>1993</year>; <volume>699</volume>: <fpage>93</fpage>–<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr5-1479164111421804">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freedman</surname><given-names>DS</given-names></name>
<name><surname>Dietz</surname><given-names>WH</given-names></name>
<name><surname>Srinivasan</surname><given-names>SR</given-names></name>
<name><surname>Berenson</surname><given-names>GS</given-names></name>
</person-group>. <article-title>The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study</article-title>. <source>Pediatrics</source> <year>1999</year>; <volume>103</volume>: <fpage>1175</fpage>–<lpage>1182</lpage>.</citation>
</ref>
<ref id="bibr6-1479164111421804">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crouse</surname><given-names>JR</given-names><suffix>3rd</suffix></name>
<name><surname>Craven</surname><given-names>TE</given-names></name>
<name><surname>Hagaman</surname><given-names>AP</given-names></name>
<name><surname>Bond</surname><given-names>MG</given-names></name>
</person-group>. <article-title>Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery</article-title>. <source>Circulation</source> <year>1995</year>; <volume>92</volume>: <fpage>1141</fpage>–<lpage>1147</lpage>.</citation>
</ref>
<ref id="bibr7-1479164111421804">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cupini</surname><given-names>LM</given-names></name>
<name><surname>Pasqualetti</surname><given-names>P</given-names></name>
<name><surname>Diomedi</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Carotid artery intima-media thickness and lacunar versus nonlacunar infarcts</article-title>. <source>Stroke</source> <year>2002</year>; <volume>33</volume>: <fpage>689</fpage>–<lpage>694</lpage>.</citation>
</ref>
<ref id="bibr8-1479164111421804">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>PH</given-names></name>
<name><surname>Dawson</surname><given-names>JD</given-names></name>
<name><surname>Riley</surname><given-names>WA</given-names></name>
<name><surname>Lauer</surname><given-names>RM</given-names></name>
</person-group>. <article-title>Carotid intimal-media thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study</article-title>. <source>Circulation</source> <year>2001</year>; <volume>104</volume>: <fpage>2815</fpage>–<lpage>2819</lpage>.</citation>
</ref>
<ref id="bibr9-1479164111421804">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsumoto</surname><given-names>K</given-names></name>
<name><surname>Sera</surname><given-names>Y</given-names></name>
<name><surname>Nakamua</surname><given-names>H</given-names></name>
<name><surname>Ueki</surname><given-names>Y</given-names></name>
<name><surname>Miyake</surname><given-names>S</given-names></name>
</person-group>. <article-title>Correlation between common carotid arterial wall thickness and ischemic stroke in patients with type 2 diabetes mellitus</article-title>. <source>Metabolism</source> <year>2002</year>; <volume>51</volume>: <fpage>244</fpage>–<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr10-1479164111421804">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Otsuji</surname><given-names>S</given-names></name>
<name><surname>Shibata</surname><given-names>H</given-names></name>
<name><surname>Umeda</surname><given-names>M</given-names></name>
</person-group>. <article-title>Turbidimetric immunoassay of serum C-reactive protein</article-title>. <source>Clin Chem</source> <year>1982</year>; <volume>28</volume>: <fpage>2121</fpage>–<lpage>2124</lpage>.</citation>
</ref>
<ref id="bibr11-1479164111421804">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khaw</surname><given-names>KT</given-names></name>
<name><surname>Wareham</surname><given-names>N</given-names></name>
</person-group>. <article-title>Glycated hemoglobin as a marker of cardiovascular risk</article-title>. <source>Curr Opin Lipidol</source> <year>2006</year>; <volume>17</volume>: <fpage>637</fpage>–<lpage>643</lpage>.</citation>
</ref>
<ref id="bibr12-1479164111421804">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hannon</surname><given-names>TS</given-names></name>
<name><surname>Rao</surname><given-names>G</given-names></name>
<name><surname>Arslanian</surname><given-names>SA</given-names></name>
</person-group>. <article-title>Childhood obesity and type 2 diabetes mellitus</article-title>. <source>Pediatrics</source> <year>2005</year>; <volume>116</volume>: <fpage>473</fpage>–<lpage>480</lpage>.</citation>
</ref>
<ref id="bibr13-1479164111421804">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lonn</surname><given-names>E</given-names></name>
</person-group>. <article-title>Carotid artery intima-media thickness–a new noninvasive gold standard for assessing the anatomic extent of atherosclerosis and cardiovascular risk?</article-title> <source>Clin Invest Med</source> <year>1999</year>; <volume>22</volume>: <fpage>158</fpage>–<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr14-1479164111421804">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Groot</surname><given-names>E</given-names></name>
<name><surname>van Leuven</surname><given-names>SI</given-names></name>
<name><surname>Duivenvoorden</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis</article-title>. <source>Nat Clin Pract Cardiovasc Med</source> <year>2008</year>; <volume>5</volume>: <fpage>280</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr15-1479164111421804">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Temelkova-Kurktschiev</surname><given-names>TS</given-names></name>
<name><surname>Koehler</surname><given-names>C</given-names></name>
<name><surname>Leonhardt</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors</article-title>. <source>Diabetes Care</source> <year>1999</year>; <volume>22</volume>: <fpage>333</fpage>–<lpage>338</lpage>.</citation>
</ref>
<ref id="bibr16-1479164111421804">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mohan</surname><given-names>V</given-names></name>
<name><surname>Ravikumar</surname><given-names>R</given-names></name>
<name><surname>Shanthi Rani</surname><given-names>S</given-names></name>
<name><surname>Deepa</surname><given-names>R</given-names></name>
</person-group>. <article-title>Intimal medial thickness of the carotid artery in South Indian diabetic and non-diabetic subjects: the Chennai Urban Population Study (CUPS)</article-title>. <source>Diabetologia</source> <year>2000</year>; <volume>43</volume>: <fpage>494</fpage>–<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr17-1479164111421804">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nathan</surname><given-names>DM</given-names></name>
<name><surname>Meigs</surname><given-names>J</given-names></name>
<name><surname>Singer</surname><given-names>DE</given-names></name>
</person-group>. <article-title>The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is … or is it?</article-title> <source>Lancet</source> <year>1997</year>; <volume>350</volume>: (<issue>Suppl 1</issue>): <fpage>S14</fpage>–<lpage>S19</lpage>.</citation>
</ref>
<ref id="bibr18-1479164111421804">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krolewski</surname><given-names>AS</given-names></name>
<name><surname>Kosinski</surname><given-names>EJ</given-names></name>
<name><surname>Warram</surname><given-names>JH</given-names></name>
<etal/>
</person-group>. <article-title>Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus</article-title>. <source>Am J Cardiol</source> <year>1987</year>; <volume>59</volume>: <fpage>750</fpage>–<lpage>755</lpage>.</citation>
</ref>
<ref id="bibr19-1479164111421804">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barrett-Connor</surname><given-names>E</given-names></name>
</person-group>. <article-title>Does hyperglycemia really cause coronary heart disease?</article-title> <source>Diabetes Care</source> <year>1997</year>; <volume>20</volume>: <fpage>1620</fpage>–<lpage>1623</lpage>.</citation>
</ref>
<ref id="bibr20-1479164111421804">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shah</surname><given-names>AS</given-names></name>
<name><surname>Dolan</surname><given-names>LM</given-names></name>
<name><surname>Kimball</surname><given-names>TR</given-names></name>
<etal/>
</person-group>. <article-title>Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk factors on early atherosclerotic vascular changes in adolescents and young adults with type 2 diabetes mellitus</article-title>. <source>J Clin Endocrinol Metab</source> <year>2009</year>; <volume>94</volume>: <fpage>3740</fpage>–<lpage>3745</lpage>.</citation>
</ref>
<ref id="bibr21-1479164111421804">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Urbina</surname><given-names>EM</given-names></name>
<name><surname>Kimball</surname><given-names>TR</given-names></name>
<name><surname>McCoy</surname><given-names>CE</given-names></name>
<name><surname>Khoury</surname><given-names>PR</given-names></name>
<name><surname>Daniels</surname><given-names>SR</given-names></name>
<name><surname>Dolan</surname><given-names>LM</given-names></name>
</person-group>. <article-title>Youth with obesity and obesity-related type 2 diabetes mellitus demonstrate abnormalities in carotid structure and function</article-title>. <source>Circulation</source> <year>2009</year>; <volume>119</volume>: <fpage>2913</fpage>–<lpage>2919</lpage>.</citation>
</ref>
<ref id="bibr22-1479164111421804">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lopes-Virella</surname><given-names>ME</given-names></name>
<name><surname>Carter</surname><given-names>RE</given-names></name>
<name><surname>Gilbert</surname><given-names>GE</given-names></name>
<etal/>
</person-group>. <article-title>Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications</article-title>. <source>Diabetes Care</source> <year>2008</year>; <volume>31</volume>: <fpage>2006</fpage>–<lpage>2012</lpage>.</citation>
</ref>
<ref id="bibr23-1479164111421804">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Després</surname><given-names>JP</given-names></name>
<name><surname>Lamarche</surname><given-names>B</given-names></name>
<name><surname>Mauriège</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Hyperinsulinemia as an independent risk factor for ischemic heart disease</article-title> <source>N Engl J Med</source> <year>1996</year>; <volume>334</volume>: <fpage>952</fpage>–<lpage>957</lpage>.</citation>
</ref>
<ref id="bibr24-1479164111421804">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dandona</surname><given-names>P</given-names></name>
<name><surname>Aljada</surname><given-names>A</given-names></name>
<name><surname>Mohanty</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Insulin inhibits intranuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?</article-title> <source>J Clin Endocrinol Metab</source> <year>2001</year>; <volume>86</volume>: <fpage>3257</fpage>–<lpage>3265</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>